Live feed10:16:00·667dPRReleasevia QuantisnowIntellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) AmyloidosisByQuantisnow·Wall Street's wire, on your screen.NTLA· Intellia Therapeutics Inc.Health Care
